Bortezomib-Based Therapy, without Stem Cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t(4;14)

被引：0
|
作者：
Reece, Donna E. [1 ]
Rodriguez, Giovanni Piza [1 ]
Belch, Andrew [2 ]
Szwajcer, David [3 ]
Pantoja, Mariela [1 ]
Kovacs, Michael [4 ]
Shustik, Chaim [5 ]
Bahlis, Nizar J. [6 ]
White, Darrell J. [7 ]
Chen, Christine [1 ]
Kukreti, Vishal [1 ]
Anglin, Peter [1 ]
Stewart, A. Keith [8 ]
Trudel, Suzanne [1 ]
机构：
[1] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada
[2] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[3] CancerCare Manitoba, Hematol, Winnipeg, MB, Canada
[4] London Hlth Sci Ctr, London, ON, Canada
[5] Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada
[6] Univ Calgary, Dept Hematol, Calgary, AB, Canada
[7] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[8] Mayo Clin Scottsdale, Scottsdale, AZ USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1485 / 1486
页数：2
相关论文
共 50 条
  • [41] Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
    Elias K. Mai
    Thomas Hielscher
    Uta Bertsch
    Jana Schlenzka
    Hans J. Salwender
    Markus Munder
    Christian Gerecke
    Ulrich Dührsen
    Peter Brossart
    Kai Neben
    Jens Hillengass
    Marc S. Raab
    Maximilian Merz
    Marc-Andrea Baertsch
    Anna Jauch
    Dirk Hose
    Hans Martin
    Hans-Walter Lindemann
    Igor W. Blau
    Christof Scheid
    Katja C. Weisel
    Hartmut Goldschmidt
    Leukemia, 2019, 33 : 258 - 261
  • [42] Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation
    Hummel, Manuela
    Hielscher, Thomas
    Emde-Rajaratnam, Martina
    Salwender, Hans
    Beck, Susanne
    Scheid, Christof
    Bertsch, Uta
    Goldschmidt, Hartmut
    Jauch, Anna
    Moreaux, Jerome
    Seckinger, Anja
    Hose, Dirk
    JCO PRECISION ONCOLOGY, 2024, 8
  • [43] Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
    Poenisch, Wolfram
    Ploetze, Madlen
    Holzvogt, Bruno
    Andrea, Marc
    Schliwa, Thomas
    Zehrfeld, Thomas
    Hammerschmidt, Doreen
    Schwarz, Maik
    Edelmann, Thomas
    Becker, Cornelia
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Kreibich, Ute
    Gutsche, Kerstin
    Reifenrath, Kolja
    Schwarzbach, Heidrun
    Heyn, Simone
    Franke, Georg-Nikolaus
    Jentzsch, Madlen
    Leiblein, Sabine
    Schwind, Sebastian
    Lange, Thoralf
    Vucinic, Vladan
    Alali, Haifa-Katrin
    Niederwieser, Dietger
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (11) : 2013 - 2022
  • [44] Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma
    Wolfram Poenisch
    Madlen Plötze
    Bruno Holzvogt
    Marc Andrea
    Thomas Schliwa
    Thomas Zehrfeld
    Doreen Hammerschmidt
    Maik Schwarz
    Thomas Edelmann
    Cornelia Becker
    Franz Albert Hoffmann
    Andreas Schwarzer
    Ute Kreibich
    Kerstin Gutsche
    Kolja Reifenrath
    Heidrun Schwarzbach
    Simone Heyn
    Georg-Nikolaus Franke
    Madlen Jentzsch
    Sabine Leiblein
    Sebastian Schwind
    Thoralf Lange
    Vladan Vucinic
    Haifa-Katrin AlAli
    Dietger Niederwieser
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 2013 - 2022
  • [45] Intensive therapy with bortezomib and melphalan and autologous stem cell transplantation for patients with multiple myeloma
    Luo, Y.
    Tan, Y.
    He, J.
    Shi, J.
    Wu, W.
    Han, X.
    Zheng, G.
    Wei, G.
    Zheng, W.
    Ye, X.
    Cai, Z.
    Huang, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S264 - S264
  • [46] High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy
    Huang, Wenrong
    Li, Jian
    Li, Honghua
    Kang, Wenying
    Bo, Jian
    Zhao, Yu
    Gao, Chunji
    Zhou, Daobin
    Yu, Li
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2507 - 2510
  • [47] Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma
    Chan, Kah-Lok
    Filshie, Robin
    Nandurkar, Harshal
    Quach, Hang
    LEUKEMIA & LYMPHOMA, 2015, 56 (07) : 2185 - 2186
  • [48] Prognostic Significance of Blood Transfusion in Newly Diagnosed Multiple Myeloma Patients without Autologous Hematopoietic Stem Cell Transplantation
    Fan, Liping
    Fu, Danhui
    Zhang, Jinping
    Huang, Haobo
    Wang, Qingqing
    Ye, Yamei
    Xie, Qianling
    BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [49] Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma
    Liapis, Konstantinos
    Kastritis, Efstathios
    Bagratouni, Tina
    Vassiliou, Spyridoula
    Papachristidis, Alexandros
    Charitaki, Evangelia
    Alevizopoulos, Nektarios
    Harhalakis, Nikolaos
    Terpos, Evangelos
    Delimpasi, Sosanna
    Dimopoulos, Meletios A.
    JOURNAL OF BUON, 2015, 20 (05): : 1314 - 1321
  • [50] Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
    Shah, N.
    Weber, D.
    Orlowski, R.
    Wang, M.
    Thomas, S. K.
    Richards, T.
    Giralt, S.
    Qazilbash, M.
    Alexanian, R.
    Shah, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345